drugset / Trial / NCT02216656
Phase 2 Study of KHK7580
RandomizedParallel-groupTriple-blindTreatment
Summary
This randomized, placebo-controlled, double-blind (included open arm of KRN1493 (cinacalcet)), parallel-group, multi-center study is designed to evaluate efficacy and safety in cohorts comprising KHK7580, its placebo and KRN1493 (cinacalcet) orally administered for three weeks for secondary hyperparathyroidism patients receiving hemodialysis.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cinacalcet | Other / unclassified | — | Oral |
| Subject | EVOCALCET | Small molecule | — | Oral |